JPH11512818A - 腫瘍特異的p450蛋白質 - Google Patents
腫瘍特異的p450蛋白質Info
- Publication number
- JPH11512818A JPH11512818A JP9513217A JP51321797A JPH11512818A JP H11512818 A JPH11512818 A JP H11512818A JP 9513217 A JP9513217 A JP 9513217A JP 51321797 A JP51321797 A JP 51321797A JP H11512818 A JPH11512818 A JP H11512818A
- Authority
- JP
- Japan
- Prior art keywords
- cyp1b1
- protein
- tissue
- sample
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
- C12N9/0077—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with a reduced iron-sulfur protein as one donor (1.14.15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
- C12Y114/14—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen (1.14.14)
- C12Y114/14001—Unspecific monooxygenase (1.14.14.1)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/902—Oxidoreductases (1.)
- G01N2333/90245—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Food Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.患者からの組織試料をCYP1B1に対する認識剤と接触させ、組織試料中の癌 細胞の存在の指標として、調製試料中のCYP1B1蛋白質と認識剤との結合を検出す ることを含む、ヒト患者の組織試料中に癌細胞が存在する場合にそれを検出する 方法。 2.癌細胞の有無を試験すべき組織試料を患者から得る段階、およびヒトCYP1 B1蛋白質と反応する認識剤と調製試料を接触させる前に、試料調製段階において 調製試料を作製する段階を含む、請求項1記載の方法。 3.認識剤と試料中のCYP1B1蛋白質との結合が免疫組織化学的分析によって検 出される、請求項2記載の方法。 4.試料調製段階が、組織を固定剤と接触させ、免疫組織化学的分析に適当な 薄切片を作製することを含む、請求項3記載の方法。 5.固定剤がホルマリンである、請求項4記載の方法。 6.薄切片がワックス包埋されている、請求項4または5記載の方法。 7.免疫組織化学的分析が結合酵素標識法を含む、請求項3〜6のいずれか一 項に記載の方法。 8.試料調製段階が組織のホモジナイズを含む、請求項2記載の方法。 9.試料調製段階がミクロソームの単離をさらに含む、請求項8記載の方法。 10.調製試料中のCYP1B1蛋白質と認識剤との結合がウェスタン・ブロット分析 によって検出される、請求項8または9記載の方法。 11.ウェスタン・ブロット分析が結合酵素標識法を含む、請求項10記載の方法 。 12.調製試料中の認識剤とCYP1B1蛋白質との結合がイムノアッセイによって検 出される、請求項8記載の方法。 13.イムノアッセイが、抗体捕獲アッセイ、2抗体サンドイッチアッセイ、お よび抗原捕獲アッセイから選択される、請求項12記載の方法。 14.イムノアッセイが固相支持に基づくイムノアッセイである、請求項12記載 の方法。 15.イムノアッセイが結合酵素標識法を含む、請求項12、13、および14のいず れか一項に記載の方法。 16.認識剤がポリクローナル抗体である、前述の請求項のいずれか一項に記載 の方法。 17.認識剤がモノクローナル抗体である、請求項1〜15のいずれか一項に記載 の方法。 18.認識剤がCYP1B1蛋白質の予め選択されたエピトープを認識する、前述の請 求項のいずれか一項に記載の方法。 19.認識剤がCYP1B1蛋白質に特異的である、請求項1〜17のいずれか一項に記 載の方法。 20.組織試料が、膀胱、脳、乳房、結腸、結合組織、腎臓、肺、リンパ節、食 道、卵巣、皮膚、胃、睾丸、および子宮から選択される、前述の請求項のいずれ か一項に記載の方法。 21.CYP1B1による特異的代謝を受けやすい物質のスクリーニングまたは選択を 含み、その物質をCYP1B1代謝によって、CYP1B1を発現している腫瘍細胞を殺傷も しくは阻害する、または他の薬物に対する感受性をより向上させる毒性部分に転 換することが可能な非毒性部分に基づいて用いることを含む、癌療法に用いられ る可能性がある薬物を得る方法。 22.完全なCYP1B1蛋白質そのものの一部であるかMHC蛋白質に結合した細胞表 面上の提示の際のように何らかの分解型であるかを問わず、腫瘍細胞の表面上の CYP1B1エピトープ認識の手段と共に、薬物、治療剤、または造影剤を提供するこ とを含む、腫瘍の診断または治療において、細胞障害剤もしくは他の治療剤のタ ーゲティング、または造影剤のターゲティングを提供する方法。 23.CYP1B1が発現されている細胞に対する細胞媒介または液性免疫反応を実行 するために、CYP1B1エピトープを認識する細胞障害性またはヘルパーT細胞を活 性化することによってヒト免疫系を刺激することが可能な生物学的活性物質。 24.少なくとも1つのCYP1B1アミノ酸配列で免疫することによって免疫系を活 性化させる、請求項23記載の生物学的活性物質。 25.自殺阻害剤、またはCYP1B1の合成を減少させるためにアンチセンスRNAを 作製する手段を含む、腫瘍細胞においてCYP1B1レベルを低下させるために用いる 物 質。 26.CYP1B1プロモーターのダウンレギュレーションによって機能する、請求項 25記載の物質。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9519490.8 | 1995-09-25 | ||
GBGB9519490.8A GB9519490D0 (en) | 1995-09-25 | 1995-09-25 | Use of a cytochrome P450 enzyme in tumour cells as a marker and target |
PCT/GB1996/002368 WO1997012246A1 (en) | 1995-09-25 | 1996-09-25 | Tumour-specific p450 protein |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005193412A Division JP4463155B2 (ja) | 1995-09-25 | 2005-07-01 | 腫瘍特異的p450蛋白質 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH11512818A true JPH11512818A (ja) | 1999-11-02 |
JP3755897B2 JP3755897B2 (ja) | 2006-03-15 |
Family
ID=10781203
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51321797A Expired - Lifetime JP3755897B2 (ja) | 1995-09-25 | 1996-09-25 | 腫瘍特異的p450蛋白質 |
JP2005193412A Expired - Lifetime JP4463155B2 (ja) | 1995-09-25 | 2005-07-01 | 腫瘍特異的p450蛋白質 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005193412A Expired - Lifetime JP4463155B2 (ja) | 1995-09-25 | 2005-07-01 | 腫瘍特異的p450蛋白質 |
Country Status (9)
Country | Link |
---|---|
US (3) | US6242203B1 (ja) |
EP (2) | EP1475639B1 (ja) |
JP (2) | JP3755897B2 (ja) |
AT (2) | ATE491951T1 (ja) |
AU (1) | AU7090396A (ja) |
DE (2) | DE69633935T2 (ja) |
ES (2) | ES2233977T3 (ja) |
GB (1) | GB9519490D0 (ja) |
WO (1) | WO1997012246A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008245652A (ja) * | 2000-10-31 | 2008-10-16 | Mgi Pharma Biologics Inc | Cyp1b1核酸および使用の方法 |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19804372A1 (de) * | 1998-02-04 | 1999-08-05 | Michael W Dr Dr Dahm | Verfahren zur quantitativen Bestimmung von Tumorzellen in einer Körperflüssigkeit und dazu geeignete Testkits |
ES2226332T3 (es) | 1998-02-06 | 2005-03-16 | De Montfort University | Profarmacos activados mediante hidroxilacion. |
GB2334256A (en) | 1998-02-12 | 1999-08-18 | Univ Montfort | Hydroxylation activated prodrugs |
US6623960B1 (en) * | 1999-02-12 | 2003-09-23 | The United States Of America As Represented By The Department Of Health And Human Services | Agents that bind to and inhibit human cytochrome P450 2C8, 2C9, 2C18 and 2C19 |
GB9906380D0 (en) * | 1999-03-19 | 1999-05-12 | Melvin William T | Monoclonal antibodies specific for cypibi |
EP1241945A4 (en) * | 1999-11-15 | 2005-08-17 | Dana Farber Cancer Inst Inc | CANCER IMMUNOTHERAPY AND DIAGNOSIS USING CYTOCHROM P450 |
GB0002835D0 (en) * | 2000-02-09 | 2000-03-29 | Melvin William T | Drug resistance in cancer |
GB0007401D0 (en) | 2000-03-27 | 2000-05-17 | Cancer Res Campaign Tech | Substituted chalcones as therapeeutic compounds |
US7385023B1 (en) | 2000-11-15 | 2008-06-10 | Trustees Of Boston University | Cancer immunotherapy and diagnosis using cytochrome P450 1B1 |
JP2004529887A (ja) | 2001-02-22 | 2004-09-30 | スクール オブ ファーマシー, ユニヴァーシティ オブ ロンドン | 腫瘍治療のためのプロドラッグとしてのピロロ−インドールおよびピロロ−キノリン誘導体 |
US7192977B2 (en) | 2001-02-22 | 2007-03-20 | School Of Pharmacy | Benz-indole and benzo-quinoline derivatives as prodrugs for tumor treatment |
EP1513860A2 (en) * | 2001-08-03 | 2005-03-16 | Diversa Corporation | P450 enzymes, nucleic acids encoding them and methods of making and using them |
GB0123780D0 (en) | 2001-10-03 | 2001-11-21 | Cancer Res Ventures Ltd | Substituted chalcones as therapeutic agents |
GB0123777D0 (en) | 2001-10-03 | 2001-11-21 | Cancer Res Ventures Ltd | Substituted chalcones as therapeutic agents |
CA2715080C (en) | 2007-09-28 | 2021-09-28 | Intrexon Corporation | Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof |
GB0803071D0 (en) * | 2008-02-20 | 2008-03-26 | Care Technologies Inc | Cancer detection methods and techniques |
WO2009153131A1 (en) * | 2008-05-28 | 2009-12-23 | Basf Se | Means and methods for assessing liver enzyme induction |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2640976B1 (ja) * | 1988-12-22 | 1994-10-28 | Roussel Uclaf | |
EP0816851A3 (en) * | 1991-01-15 | 2000-08-23 | Oy Biotie Therapies | Detection of syndecan content in body fluids for indication of malignant transformation of cells |
DE4309344A1 (de) * | 1993-03-23 | 1994-09-29 | Gerhard Prof Dr Eisenbrand | Antineoplastische Mittel mit verstärkter Wirksamkeit |
-
1995
- 1995-09-25 GB GBGB9519490.8A patent/GB9519490D0/en active Pending
-
1996
- 1996-09-25 WO PCT/GB1996/002368 patent/WO1997012246A1/en active IP Right Grant
- 1996-09-25 AT AT04019264T patent/ATE491951T1/de not_active IP Right Cessation
- 1996-09-25 EP EP04019264A patent/EP1475639B1/en not_active Expired - Lifetime
- 1996-09-25 ES ES96931897T patent/ES2233977T3/es not_active Expired - Lifetime
- 1996-09-25 ES ES04019264T patent/ES2358106T3/es not_active Expired - Lifetime
- 1996-09-25 EP EP96931897A patent/EP0856157B1/en not_active Expired - Lifetime
- 1996-09-25 AT AT96931897T patent/ATE283483T1/de not_active IP Right Cessation
- 1996-09-25 DE DE69633935T patent/DE69633935T2/de not_active Expired - Lifetime
- 1996-09-25 AU AU70903/96A patent/AU7090396A/en not_active Abandoned
- 1996-09-25 JP JP51321797A patent/JP3755897B2/ja not_active Expired - Lifetime
- 1996-09-25 DE DE69638310T patent/DE69638310D1/de not_active Expired - Lifetime
- 1996-09-25 US US09/043,814 patent/US6242203B1/en not_active Expired - Lifetime
-
2001
- 2001-06-04 US US09/874,166 patent/US20020052013A1/en not_active Abandoned
-
2002
- 2002-09-23 US US10/252,850 patent/US20030087408A1/en not_active Abandoned
-
2005
- 2005-07-01 JP JP2005193412A patent/JP4463155B2/ja not_active Expired - Lifetime
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008245652A (ja) * | 2000-10-31 | 2008-10-16 | Mgi Pharma Biologics Inc | Cyp1b1核酸および使用の方法 |
Also Published As
Publication number | Publication date |
---|---|
EP0856157B1 (en) | 2004-11-24 |
EP1475639B1 (en) | 2010-12-15 |
US6242203B1 (en) | 2001-06-05 |
DE69633935D1 (de) | 2004-12-30 |
EP1475639A2 (en) | 2004-11-10 |
EP1475639A3 (en) | 2004-12-08 |
ATE491951T1 (de) | 2011-01-15 |
US20030087408A1 (en) | 2003-05-08 |
JP2006034290A (ja) | 2006-02-09 |
JP3755897B2 (ja) | 2006-03-15 |
GB9519490D0 (en) | 1995-11-29 |
ES2233977T3 (es) | 2005-06-16 |
US20020052013A1 (en) | 2002-05-02 |
ES2358106T3 (es) | 2011-05-05 |
DE69633935T2 (de) | 2005-12-22 |
JP4463155B2 (ja) | 2010-05-12 |
WO1997012246A1 (en) | 1997-04-03 |
DE69638310D1 (de) | 2011-01-27 |
AU7090396A (en) | 1997-04-17 |
ATE283483T1 (de) | 2004-12-15 |
EP0856157A1 (en) | 1998-08-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4463155B2 (ja) | 腫瘍特異的p450蛋白質 | |
US7459529B2 (en) | AIMP2-DX2 and its uses | |
CA3076730C (en) | Method for detection of cancer | |
JP3837494B2 (ja) | 可溶型rageタンパク質 | |
JP2006510008A (ja) | アクチビンβCのレベルの調節によって特徴付けられる状態のための診断方法、治療方法、および有用な薬剤 | |
JP2015172601A (ja) | 細胞を検出する方法、およびこれに有用な薬剤 | |
JPH10503365A (ja) | チロシンリン酸化crklタンパク質を発現する癌の診断および処置 | |
ES2371479T3 (es) | Uso de aimp2dx2 para el diagnóstico y tratamiento del cáncer. | |
US20090221004A1 (en) | Caspase-cleavage anti-keratin antibodies for detection of apoptosis | |
US6821725B1 (en) | Methods for the diagnosis and treatment of breast cancer | |
JP2002525098A5 (ja) | ||
US20040072189A1 (en) | Prognostic indicator | |
CN111440870B (zh) | CircZCCHC11及其翻译的肽段在肿瘤生长和转移预测、预后评估和治疗中的应用 | |
US20030176661A1 (en) | Novel antibody with specificity for colon cancer | |
WO1994011508A3 (en) | Polypeptides with specificity for neoplasias, kit, and diagnostic, vaccination, and therapeutic methods | |
US7419792B2 (en) | Laminin Receptor 1 Precursor Protein (37LRP) epitope delineated by an Hepatocellular carcinoma specific antibody | |
US7226731B1 (en) | PB 39, a gene dysregulated in prostate cancer, and uses thereof | |
KR101777085B1 (ko) | En2 단백질의 면역원성 단편 펩타이드 또는 이를 특이적으로 인식하는 항체 조성물 | |
US20050181418A1 (en) | Nuclear matrix proteins, polynucleotide sequences encoding them, and their use | |
ES2303595T3 (es) | Moleculas marcadoras asociadas con tumores pulmonares. | |
US20060292627A1 (en) | PB39, a gene dysregulated in prostate cancer, and uses thereof | |
Homma et al. | A pancreatic oncofetal antigen: Its partial purification and clinical application | |
JP2023133869A (ja) | 卵巣がん患者の予後予測用バイオマーカー | |
US20030166519A1 (en) | Novel polynucleotides and polypeptides and uses therefor | |
US20140178362A1 (en) | Methods and compositions for treating diseases targeting maba |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040608 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20040906 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20041025 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041206 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050510 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050701 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20050811 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20051206 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20051220 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100106 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110106 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120106 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130106 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130106 Year of fee payment: 7 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |